available for iOS, Android & web
August 02, 2011
GlaxoSmithKline's recently-licensed Trobalt (retigabine) should be prescribed as an add-on treatment for adults with epilepsy if other drugs have been ineffective or produced unmanageable side effects, says final guidance from NICE.
July 27, 2011
Sweden's Meda has denied rumours that Valeant Pharmaceuticals International, which is very firmly on the acquisition trail, has made a $4 billion-plus bid for the firm
June 13, 2011
GlaxoSmithKline and Valeant Pharmaceuticals International are celebrating this morning after regulators in the USA gave the green light to their epilepsy tablet Potiga
December 02, 2010
Regulatory advisors in the US have refused to back GlaxoSmithKline’s Avodart and Merck's Proscar - medicines used to treat enlarged prostates - for the prevention of prostate cancer in men.
August 31, 2010
GSK and partner Valeant have suffered a slight setback with the news that the FDA needs another three months to decide on final approval of the firms epilepsy treatment Potiga
International Clinical Researcher of the Year 2016
Last chance to enter!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions